Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-01-17
2006-01-17
Saunders, David (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C435S005000, C435S007210, C435S007400, C435S023000, C435S024000, C436S063000, C436S069000, C436S071000, C436S086000, C436S087000, C436S094000, C436S518000, C436S536000, C436S811000, C436S820000, C702S019000, C706S924000
Reexamination Certificate
active
06986995
ABSTRACT:
The present invention provides a method of diagnosing the presence or severity of liver fibrosis in an individual by detecting α2-macroglobulin (α2-MG) in a sample from the individual; detecting hyaluronic acid (HA) in a sample from the individual; detecting tissue inhibitor of metalloproteinases-1 (TIMP-1) in a sample from the individual; and diagnosing the presence or severity of liver fibrosis in the individual based on the presence or level of α2-MG, HA and TIMP-1.
REFERENCES:
patent: 5019498 (1991-05-01), Chichibu
patent: 6218129 (2001-04-01), Walsh et al.
patent: 6631330 (2003-10-01), Poynard
patent: 0 911 343 (1999-04-01), None
patent: 1 150 123 (2001-10-01), None
patent: WO 01/86304 (2001-11-01), None
Afdhal et al, Journal of Hepatology, 27, 993-1002, 1997.
Oh et al, Current Gastroenterology Reports, 3, 12-18, 2001.
Armstrong and Quigley, “α2- macroglobulin: an evolutionarily conserved arm of the innate immune system,”Develop. Compar. Immunol. 23:375-390 (1999).
Arthur et al., “Tissue inhibitors of metalloproteinases: Role in liver fibrosis and alcoholic liver disease,”Alcohol Clin. Exp. Res. 23:940-943 (1999).
Bodden et al., “Functional domains of human TIMP-1 (tissue inhibitor of metalloproteinases),”J. Biol. Chem. 269:18943-18952 (1994).
Boeker et al., “Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C,”Clin Chim Acta316:71-81 (2002).
Böker et al., “Tissue inhibitors of metalloproteinases in liver and serum/plasma in chronic active hepatitis C and HCV-induced cirrhosis,”Hepato-Gastroenterol47:812-819 (2000).
Bramley et al., “Serum hyaluronate as a marker of hepatic derangement in acute liver damage,”J. Hepatol. 13:8-13 (1991).
Brandt et al., “A convenient radiometric assay for hyaluronan,”Acta Otolaryn. 442 (Suppl.):31-35 (1987).
Bray et al., “Early changes in lung tissue hyaluronan (hyaluronic acid) and hyaluronidase bleomycin-induced alveolitis in hamsters,”Am. Rev. Respir. Dis. 3:284-288 (1991).
Brophy et al., “Tissue inhibitor of metallo-proteinases (TIMP) is matrix associated in aortic tissue: Report of a radioimmunoassay,”Biochem. Biophys. Res. Comm. 167:898-903 (1990).
Castera et al., “Serum laminin and type IV collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis,”J. Hepatol. 32:412-418 (2000).
Cawston et al., “Protein Inhibitors of Metalloproteinases” in Barrett and Salvesen (Eds),Proteinase InhibitorsAmsterdam Elsevier Science Publishers pp. 589-610 (1986).
Cazzolla et al., “Development of an enzyme-linked immunosorbent assay, using a monoclonal antibody against α2-macroglobulin, for diagnosis of systemic lupus erythematosus,”Clinical Biochemistry32:249-255 (1999).
Chichibu et al., “Assay of serum hyaluronic acid in clinical application,”Clin. Chim. Acta181:317-323 (1989).
Delpech et al., “Immunoenzymoassay of the hyaluronic acid-hyaluronectin interaction: application to the detection of hyaluronic acid in serum of normal subjects and cancer patients,”Anal. Biochem. 149:555-565 (1985).
Docherty et al., “Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity,”Nature318:66-69 (1985).
Emlen et al., “Measurement of serum hyaluronic acid in patients with rheumatoid arthritis: Correlation with disease activity,”J. Rheum. 23:974-978 (1996).
Engstrom-Laurent et al., “Concentration of sodium hyaluronate in serum,”Scand. J. Clin. Lab. Invest. 45:497-504 (1985).
Fink et al., “Measurement of proteins with the Behring Nephelometer. A multicentre evaluation,”J. Clin. Chem. Clin. Biochem. 27:261-276 (1989).
Fortunato et al., “Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis,”Clin. Chem. 47:1696-1700 (2001).
Gabrielli et al., “Serum laminin P1 in chronic viral hepatitis: correlations with liver histological activity and diagnositic value,”Clin. Chim. Acta252:171-180 (1996).
Gabrielli et al., “Serum laminin and type III procollagen in chronic hepatitis C. Diagnositic value in the assessment of disease activity and fibrosis,”Clin. Chem. Acta265:21-31 (1997).
Ganrot, “Determination of α2-macroglobin as trypsin-protein esterase,”Clin. Chim. Acta14:493-501 (1966).
Goldberg et al., “Elevated plasma levels of hyaluronate in patients with osteoarthritis and rheumatoid arthritis,”Arthritis Rheum. 34:799-807 (1991).
Goldberg, “Enzyme-linked immunosorbent assay for hyaluronan using cartilage proteoglycan and an antibody to keratan sulfate,”Anal. Biochem. 174:448-458 (1988).
Groft et al., “Differential expression and localization of TIMP-1 and TIMP-4 in human gliomas,”Br. J. Cancer85:55-63 (2001).
Guechot et al., “Diagnositc accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis,”Clin. Chem. 42:558-563 (1996).
Hakala et al., “Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family,”J. Biol. Chem. 268:25803-25810 (1993).
Hall and Roberts, “Physical and chemical properties of human plasma α2-macroglobin,”Biochem. J. 171:27-38 (1978).
Hayasaka and Saisho, “Serum markers as tools to monitor liver fibrosis,”Digestion59:381-384 (1998).
Imber and Pizzo, “Clearance and binding of two electrophoretic “fast” forms of human α2-macroglobin,”J. Biol. Chem. 256:8134-8139 (1981).
Imbert-Bismut et al., “Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study,”Lancet357:1069-1075 (2001).
Janowska-Wieczorek et al., “Differential MMP and TIMP production by human marrow and peripheral blood CD34'cells in response to chemokines,”Exp. Hematol. 28:1274-1285 (2000).
Jeffers et al., “Procollagen-III peptide and chronic viral C hepatitis,”Am. J. Gastroenterol. 90:1437-1440 (1995).
Johansen et al., “Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis?,”Scand. J. Gastroenterol. 32:582-590 (1997).
Johansen et al., “A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid,”Br. J. Rheumatology32:949-955 (1993).
Johansen et al., “Serum YKL-40 is increased in patients with hepatic fibrosis”J. Hepatol. 323:911-920 (2000).
Johansen et al., “Indentification of proteins secreted by human osteoblastic cells in culture,”J. Bone Miner. Res. 7:501-511 (1992).
Kasahara et al., “Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C,”J Hepatol26:574-583 (1997).
Knodell et al., “Formulation and application of a numerical scoring system for assessing historical activity in asymptomatic chronic active hepatitis,”Hepatology1:431-435 (1981).
Kodama et al. “Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases,”J. Immunol. Methods127:103-108 (1990).
Konttinen et al., “Serum baseline hyaluronate and disease activity in rheumatoid arthritis”Clin. Chimica Acta193:39-47 (1990).
Kossakowska et al., “Altered balance between matrix metalloproteinases ans their inhibitors in experimental biliary fibrosis,”Amer. J. Patholody153:1895-1902 (1998).
Kropf et al., “Efficacy of serum laminin measurement for diagnosis of fibrotic liver diseases,”Clin. Chem. 34:2026-2030 (1988).
Laurent and Tengbl
Oh Esther H.
Rose Steven L.
Walsh Michael J.
Prometheus Laboratories Inc.
Saunders David
Townsend and Townsend / and Crew LLP
LandOfFree
Methods of diagnosing liver fibrosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of diagnosing liver fibrosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of diagnosing liver fibrosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3538307